Galera Therapeutics fetches $150 mln Series C

Malvern, Pennsylvania-based Galera Therapeutics Inc, a clinical-stage biotechnology company, has secured $150 million in Series C financing. Clarus led the round with participation from Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital, Tekla Capital Management LLC, Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures and Sofinnova Ventures. In conjunction with the funding, Dr. Emmett T. Cunningham Jr, a managing director at Clarus, will join Galera’s board of directors.

Source: Press Release